Optimal Balance of Benefit Versus Risk for Tafenoquine in Plasmodium Vivax Malaria Treatment

A recent study published in the Malaria Journal has highlighted the effectiveness of a single 300 mg dose of tafenoquine in combination with chloroquine for the radical cure of Plasmodium vivax malaria. This new treatment approach is expected to improve patient adherence and overall treatment outcomes, offering a favorable benefit-risk profile for the radical cure of vivax malaria.